TrovaGene Inc (NASDAQ:TROV) saw a large drop in short interest in June. As of June 30th, there was short interest totalling 464,400 shares, a drop of 10.6% from the May 30th total of 519,300 shares. Currently, 11.6% of the shares of the stock are short sold. Based on an average daily volume of 375,900 shares, the short-interest ratio is currently 1.2 days.
Shares of NASDAQ TROV traded down $0.10 during trading on Friday, hitting $2.15. 64,672 shares of the company were exchanged, compared to its average volume of 52,060. TrovaGene has a 12-month low of $2.14 and a 12-month high of $9.65. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.76 and a quick ratio of 3.76. The company’s fifty day moving average is $2.68. The stock has a market cap of $11.70 million, a price-to-earnings ratio of -0.26 and a beta of 0.77.
TrovaGene (NASDAQ:TROV) last posted its quarterly earnings results on Tuesday, May 7th. The medical research company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.05. TrovaGene had a negative return on equity of 121.65% and a negative net margin of 3,540.91%. The business had revenue of $0.16 million for the quarter. On average, analysts anticipate that TrovaGene will post -4.02 EPS for the current year.
A number of research analysts have weighed in on TROV shares. Maxim Group set a $8.00 price objective on TrovaGene and gave the company a “buy” rating in a report on Thursday, May 23rd. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Zacks Investment Research lowered Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a report on Thursday, May 9th. Finally, Noble Financial set a $2.00 price objective on Pyxis Tankers and gave the company a “buy” rating in a report on Friday, May 24th.
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Recommended Story: Why Net Income is Important to Investors
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.